scholarly journals Risk Factors Associated With Early Recurrence of Borderline Resectable Pancreatic Ductal Adenocarcinoma After Neoadjuvant Chemoradiation Therapy and Curative Resection

2019 ◽  
Vol 39 (8) ◽  
pp. 4431-4440 ◽  
Author(s):  
NOBUHIRO TSUCHIYA ◽  
RYUSEI MATSUYAMA ◽  
TAKASHI MURAKAMI ◽  
YASUHIRO YABUSHITA ◽  
YU SAWADA ◽  
...  
Keyword(s):  
Risk Factors ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Curative Resection ◽  
Early Recurrence ◽  
Neoadjuvant Chemoradiation ◽  
Chemoradiation Therapy ◽  
Ductal Adenocarcinoma ◽  
Borderline Resectable ◽  
Factors Associated ◽  
Neoadjuvant Chemoradiation Therapy

scholarly journals The spectrum of histopathological changes encountered in pancreatectomy specimens after neoadjuvant chemoradiation, including subtle and less-well-recognised changes

2016 ◽  
Vol 69 (6) ◽  
pp. 463-471 ◽  
Author(s):  
Sangeetha N Kalimuthu ◽  
Stefano Serra ◽  
Neesha Dhani ◽  
Runjan Chetty
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Treatment Modality ◽  
Neoadjuvant Chemoradiation ◽  
Chemoradiation Therapy ◽  
Ductal Adenocarcinoma ◽  
Histopathological Changes ◽  
Borderline Resectable ◽  
Histological Changes ◽  
Histological Features ◽  
Therapy Treatment

Preoperative (neoadjuvant) chemoradiation therapy/treatment (NCRT) is emerging as an important treatment modality in borderline resectable pancreatic ductal adenocarcinoma (PDAC). The constellation of histopathological changes secondary to chemoradiation is diverse and has been well documented, particularly in other gastrointestinal organs such as the oesophagus and colorectum. However, the histological changes specific to the pancreas have not been fully characterised and described. This review aims to provide a detailed catalogue of histological features associated with NCRT-treated PDAC and highlight any subtle, less-recognised changes.

scholarly journals Liver Metastases in Newly Diagnosed Pancreatic Ductal Adenocarcinoma: A Population Based Analysis

2020 ◽  
Author(s):  
Guoyi Wu ◽  
Xiaoben Pan ◽  
Baohua Wang ◽  
Xiaolei Zhu ◽  
Jing Wu ◽  
...  
Keyword(s):  
Risk Factors ◽  
Liver Metastases ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Tumor Size ◽  
Cox Regression ◽  
Population Based ◽  
The Body ◽  
Ductal Adenocarcinoma ◽  
Rank Test ◽  
Factors Associated

Abstract Background Estimates of the incidence and prognosis of developing liver metastases at the pancreatic ductal adenocarcinoma (PDAC) diagnosis are lacking.Methods In this study, we analyzed the association of liver metastases and the PDAC patients outcome. The risk factors associated with liver metastases in PDAC patients were analyzed using multivariable logistic regression analysis. The overall survival (OS) was estimated using Kaplan-Meier curves and log-rank test. Cox regression was performed to identify factors associated with OS.Results Patients with primary PDAC in the tail of the pancreas had a higher incidence of liver metastases (62.2%) than those with PDAC in the head (28.6%). Female gender, younger age, primary PDAC in the body or tail of the pancreas, and larger primary PDAC tumor size were positively associated with the occurrence of liver metastases. The median survival of patients with liver metastases was significantly shorter than that of patients without liver metastases. Older age, unmarried status, primary PDAC in the tail of the pancreas, and tumor size ≥4 cm were risk factors for OS in the liver metastases cohort.Conclusions Population-based estimates of the incidence and prognosis of PDAC with liver metastases may help decide whether diffusion-weighted magnetic resonance imaging should be performed in patients with primary PDAC in the tail or body of the pancreas. The location of primary PDAC should be considered during the diagnosis and treatment of primary PDAC.

Sign in / Sign up

Export Citation Format

Share Document